Consolidated Statements of Cash Flows (USD $)	6 Months Ended		336 Months Ended
	Sep. 30, 2011	Sep. 30, 2010	Sep. 30, 2011
Net loss	$ (3,039,377)	$ (6,236,958)	$ (51,511,323)
Depreciation and amortization	9,773	9,383	1,087,752
Amortization of deferred consulting fees			109,000
Loss on settlement of accrued interest and damages		68,703	1,037,951
Valuation allowance on note receivable		300,000
Gain on sale of property and equipment			(13,065)
Gain on settlement of debt			(131,175)
Loss on settlement of accrued legal liabilities			142,245
Stock based compensation	448,062	1,298,168	4,497,801
Legal fees paid through the issuance of convertible debt			63,412
Fair market value of common shares donated to research institute			25,000
Loss on debt extinguishment		2,226,924	5,978,865
Fair market value of warrants issued in connection with accounts payable and debt			2,715,736
Fair market value of conditional warrants that subsequently were issued			106,201
Non cash interest expense	538,736	1,675,693	1,791,425
Liquidated damages			685,800
Fair market value of common stock, warrants and options issued for services	249,878	382,217	5,594,577
Change in fair value of derivative liabilities	(1,521,502)	(1,668,877)	(6,282,598)
Termination fees paid through the issuance of notes payable	360,186		360,186
Patent license fees paid in stock			45,250
Amortization of debt discount and deferred financing costs	1,522,486	848,199	8,175,951
Impairment of intangible assets			1,313,253
Deferred compensation forgiven			217,223
Prepaid expenses and other assets	18,394	20,021	221,008
Accounts payable and other current liabilities	377,318	113,278	3,351,132
Due to related parties			1,268,383
Net cash used in operating activities	(1,036,046)	(963,249)	(19,150,010)
Purchases of property and equipment	(1,735)	(875)	(294,194)
Additions to patents and patents pending		(5,873)	(407,235)
Proceeds from the sale of property and equipment			17,065
Cash of acquired company			10,728
Net cash used in investing activities	(1,735)	(6,748)	(673,636)
Proceeds from the issuance of notes payable			2,350,000
Principal repayments of notes payable	(5,000)		(381,500)
Net proceeds from the issuance of convertible notes payable	872,656	1,105,000	6,523,921
Proceeds from the issuance of common stock		283,600	10,753,535
Proceeds from collection of secured notes receivable	200,000		700,000
Professional fees related to registration statement			(76,731)
Net cash provided by financing activities	1,067,656	1,388,600	19,869,225
Net (decrease) increase in cash	29,875	418,603	45,579
Cash at beginning of period	15,704	67,950
Cash at end of period	45,579	486,553	45,579
Interest			266,975
Income taxes			13,346
Derivative liabilities recorded in connection with embedded conversion feature of convertible notes and/or warrants		3,200,961
Debt and accrued interest converted to common stock	1,472,611	385,508	7,824,434
Deferred financing costs recorded in connection with debt restructuring		80,054	80,054
Debt discount recorded in connection with beneficial conversion feature of convertible notes and related warrants	827,130	75,000	4,000,059
Issuance of convertible notes in settlement of accrued legal fees		35,469	35,469
Reclassification of accounts payable to notes payable			24,001
Reclassification of warrant derivative liability into equity	247,608		666,800
Additional convertible debt issued in debt restructuring			573,211
Stock option exercise by director for accrued expenses			95,000
Issuance of common stock, warrants and options in settlement of accrued expenses and due to related parties			1,003,273
Issuance of common stock in connection with acquisition of patent pending and with license agreements			118,000
Net assets of entities acquired in exchange for equity securities			1,597,867
Debt placement fees paid by issuance of warrants			856,845
Common stock issued for prepaid expenses			$ 161,537